Efficacy and Safety of Different Doses of Rivaroxaban in Elderly Chinese Patients With Nonvalvular Atrial Fibrillation

Launched by THE AFFILIATED NANJING DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL · Dec 5, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of different doses of a medication called rivaroxaban in elderly Chinese patients with a heart condition known as nonvalvular atrial fibrillation, which can cause irregular heartbeats. The trial will involve 300 participants, aged 75 and older, and will follow them for two years to see how well the different doses work and if there are any side effects.

To participate, individuals must be 75 years or older and have been diagnosed with nonvalvular atrial fibrillation. However, some people won't be eligible, including those with certain health conditions, like severe anemia or kidney problems, and those who are pregnant or breastfeeding. This trial is not yet recruiting participants, but it aims to provide important information about how different doses of rivaroxaban can help manage this heart condition in older adults. If you think you might be eligible, keep an eye out for more information as the trial begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age≥75 years
• • Chinese patient: male or female
• • Patients had to be diagnosed as nonvalvular atrial fibrillation (NVAF)
• Exclusion Criteria:
• • Patients with anemia (hemoglobin\<100g/L), known human immunodeficiency virus infection, female patients who were pregnant or lactating and patients for whom warfarin was contraindicated, were also excluded
• • Patients with calculated creatine clearance vulue\<30ml/min
• • Patients expected to chronically use a non-steroidal anti-inflammatory agent (except for external preparations) and those treated with a strong cytochrome P4503A4 inhibitor (eg, ketoconazole, clarithromycin, or protease inhibitors) or a strong cytochrome P450 3A4 inducer (eg, rifampicin) during the trial